SIGLEC-7-TF tag mRNA-LNP
SIGLEC7, also known as CD328, is a protein belonging to the sialic acid-binding immunoglobulin-like lectin (SIGLEC) family, encoded by the SIGLEC7 gene. Proteins of this family are expressed on the surface of immune cells, are a subset of type I lectins, and bind sialic acid. These SIGLEC proteins have been designated as glycoimmune checkpoints. Their ligands are sialylated glycan proteins that are abnormally expressed on tumor cells. Inhibitory SIGLECs (e.g. SIGLEC-7 and -9) are found on immune cells such as natural killer (NK) and T cells by interacting with their ligands and inhibit immune signaling pathways to dampen immune responses. Studies have found that SIGLEC-7 is associated with a reduction in CD8+ T cell effector functions, including cytotoxicity and cytokine production. SIGLEC-7 was found to be highly expressed in primary leukemia cells and stem cells from patients with acute myeloid leukemia (AML). This may adversely affect the effector responses of SIGLEC-7+ CD8+ T cells in the blood and bone marrow of AML patients.
This product is designed as a tool for the delivery and expression of human TF tagged SIGLEC7 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of SIGLEC7-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The SIGLEC7-TF fusion protein is approximately 53 kD, consisting of SIGLEC7 (467 amino acids) and a C-terminal TF tag (15 amino acids). The GenPept accession number for SIGLEC7 is NP_055200.